Clinical trial NCT02502981 - References

Renal Insufficiency, Chronic — Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD

Citation(s)

•   Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM
  Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999 May 11;99(18):2434-9.
•   Brown NJ
  Aldosterone and vascular inflammation. Hypertension. 2008 Feb;51(2):161-7. doi: 10.1161/HYPERTENSIONAHA.107.095489. Epub 2008 Jan 2. Review.
•   Chue CD, Townend JN, Steeds RP, Ferro CJ
  Arterial stiffness in chronic kidney disease: causes and consequences. Heart. 2010 Jun;96(11):817-23. doi: 10.1136/hrt.2009.184879. Epub 2010 Apr 20. Review.
•   Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS
  Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7;298(17):2038-47.
•   Edwards NC, Ferro CJ, Kirkwood H, Chue CD, Young AA, Stewart PM, Steeds RP, Townend JN
  Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010 Nov 15;106(10):1505-11. doi: 10.1016/j.amjcard.2010.07.018.
•   Edwards NC, Ferro CJ, Townend JN, Steeds RP
  Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart. 2008 Aug;94(8):1038-43. doi: 10.1136/hrt.2007.137539. Epub 2008 Feb 28.
•   Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN
  Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009 Aug 4;54(6):505-12. doi: 10.1016/j.jacc.2009.03.066.
•   Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY
  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. Erratum in: N Engl J Med. 2008;18(4):4.
•   Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG
  Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 2006 May;69(10):1839-45.
•   Matsumoto Y, Hamada M, Hiwada K
  Aortic distensibility is closely related to the progression of left ventricular hypertrophy in patients receiving hemodialysis. Angiology. 2000 Nov;51(11):933-41.
•   National Kidney Foundation
  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
•   Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J
  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709-17.
•   Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T
  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005 Apr 25;165(8):936-46.
•   Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK
  Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000 Oct;141(10):3871-8.
•   Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J
  Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens. 2003 Jul;21(7):1291-8.
•   Struthers AD
  Aldosterone: cardiovascular assault. Am Heart J. 2002 Nov;144(5 Suppl):S2-7. Review.
•   Zannad F, Alla F, Dousset B, Perez A, Pitt B
  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000 Nov 28;102(22):2700-6. Erratum in: Circulation 2001 Jan 23;103(3):476.

A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)

Details for clinical trial NCT02502981